ABO and Rh Blood Group Systems, Inheritance, and Rh Incompatibility

Fundamentals of the ABO Blood Group System

  • Discovery: The ABO blood group system was discovered by Karl Landsteiner.
  • Physiological Basis: Classification is based on the presence or absence of two surface antigens, designated as A and B, located on red blood cells (RBCs), alongside corresponding antibodies present in plasma.
  • Surface Antigens: Antigens are specific molecular structures or substances located directly on the outer membrane surface of RBCs.
  • Plasma Antibodies: Antibodies are defensive proteins residing within the blood plasma.
  • Agglutination Reaction: The reaction between a specific surface antigen and its corresponding plasma antibody (e.g., A antigen reacting with Anti-A antibody) results in agglutination, which is the clumping of RBCs.
  • Clinical Transfusion Mandate: A compatibility test must always be conducted prior to performing any blood transfusion to avoid severe agglutination reactions.

Classification and Specifics of ABO Blood Groups

  • Blood Group A:
    • RBC Surface Antigen: A antigen.
    • Plasma Antibody: Anti-B antibody.
  • Blood Group B:
    • RBC Surface Antigen: B antigen.
    • Plasma Antibody: Anti-A antibody.
  • Blood Group AB:
    • RBC Surface Antigens: Both A and B antigens.
    • Plasma Antibodies: None (neither Anti-A nor Anti-B antibodies are present in plasma).
  • Blood Group O:
    • RBC Surface Antigens: None (neither A nor B antigen is present on the RBC surface).
    • Plasma Antibodies: Both Anti-A and Anti-B antibodies.
  • Universal Donor Concept:
    • Blood Group O (specifically O−O^- / O-negative) is classified as the universal donor.
    • Individuals with this blood group can donate blood to individuals of all other blood groups because their RBCs lack both A and B surface antigens.
  • Universal Recipient Concept:
    • Blood Group AB (specifically AB+AB^+ / AB-positive) is classified as the universal recipient.
    • Individuals with this blood group can receive blood from individuals of all other blood groups because their plasma contains no Anti-A or Anti-B antibodies.

Genetics and Inheritance Patterns of ABO Blood Groups

  • Chromosomal Location and Gene Control: The ABO blood group system is governed by a single gene designated as II (or ii), located on chromosome 9.
  • Hereditary Nature: Blood groups are inherited directly from parents.
  • Allelic Variants:
    • IAI^A Allele: Encodes and produces the A surface antigen.
    • IBI^B Allele: Encodes and produces the B surface antigen.
    • ii Allele: Does not produce either A or B antigen (associated with blood group O).
  • Gene Interaction and Expression Principles:
    • Codominance: The alleles IAI^A and IBI^B are codominant with respect to each other; both express simultaneously when inherited together, resulting in the AB phenotype.
    • Dominance/Recessiveness: The ii allele is completely recessive to both IAI^A and IBI^B alleles.
  • Phenotype-to-Genotype Mapping:
    • Blood Group A: Genotypes IAIAI^A I^A (homozygous) or IAiI^A i (heterozygous).
    • Blood Group B: Genotypes IBIBI^B I^B (homozygous) or IBiI^B i (heterozygous).
    • Blood Group AB: Genotype IAIBI^A I^B (heterozygous codominant).
    • Blood Group O: Genotype iii i (homozygous recessive).

The Rh Blood Group System

  • Definition and Physiological Basis: The Rh blood group system is defined by the presence or absence of another antigen known as the Rh factor (specifically designated as the D antigen) on the surface of RBCs.
  • Discovery History: Discovered in 1940 by Karl Landsteiner and Alexander Wiener. The system was named after the Rhesus monkey, in which the D antigen was first studied and identified.
  • Chromosomal Location: The Rh factor is controlled by a distinct, separate gene (for Rh+Rh^+ and Rh−Rh^-) located on chromosome 1.
  • Categorization and Population Distribution:
    • Rh-Positive (Rh+Rh^+):
    • D antigen is PRESENT on the RBC surface.
    • Accounts for approximately 80–85%80\text{--}85\% of the human population.
    • Phenotypic examples: A+A^+, B+B^+, AB+AB^+, O+O^+.
    • Rh-Negative (Rh−Rh^-):
    • D antigen is ABSENT from the RBC surface.
    • Accounts for approximately 15–20%15\text{--}20\% of the human population.
    • Phenotypic examples: A−A^-, B−B^-, AB−AB^-, O−O^-.

Sensitization Mechanisms and Rh Transfusion Rules

  • Induction of Anti-Rh Antibodies:
    • Unlike the ABO blood group system, Rh−Rh^- individuals do not naturally possess anti-Rh antibodies in their plasma.
    • Anti-Rh antibodies are produced only after an Rh−Rh^- person is exposed to Rh+Rh^+ blood.
    • Exposure occurs through two primary routes:
    1. Blood transfusion containing Rh+Rh^+ blood.
    2. Gestation/pregnancy involving an Rh+Rh^+ fetus.
  • Rh Transfusion Protocols:
    • Rh+→Rh+Rh^+ \rightarrow Rh^+: An Rh+Rh^+ recipient can safely receive Rh+Rh^+ blood.
    • Rh−→Rh−Rh^- \rightarrow Rh^-: An Rh−Rh^- recipient should strictly receive only Rh−Rh^- blood.
    • Rh−←Rh+Rh^- \leftarrow Rh^+: Transfusion of Rh+Rh^+ blood into an Rh−Rh^- individual causes sensitization, triggering the immune system to synthesize anti-Rh antibodies.

Rh Incompatibility and Erythroblastosis Foetalis

  • Definition and Nomenclature: Erythroblastosis Foetalis, also known as Haemolytic Disease of the Newborn (HDN), is a medical condition in which maternal anti-Rh antibodies cross the placental barrier and destroy the erythrocytes of an Rh+Rh^+ fetus, causing severe haemolytic anaemia.
  • Parental Combination Triggering Incompatibility:
    • Mother: Rh-negative (Rh−Rh^-).
    • Father: Rh-positive (Rh+Rh^+).
    • Fetus: Rh-positive (Rh+Rh^+).
  • Mechanism during First Pregnancy:
    • During normal gestation, maternal and fetal blood supplies remain separated by the placental barrier.
    • At delivery (or during events such as miscarriage, abortion, physical trauma, or invasive procedures like amniocentesis), a small volume of fetal Rh+Rh^+ blood may leak into the maternal bloodstream.
    • The mother's immune system identifies the fetal D antigen as foreign and synthesizes anti-Rh (anti-D) antibodies, a process known as sensitization.
    • First Child Outcome: The first baby is usually born normal and unaffected because maternal antibody synthesis occurs only after exposure to fetal blood late in or after delivery.
  • Mechanism during Second Rh+Rh^+ Pregnancy:
    • The mother retains active, pre-formed anti-Rh antibodies in her bloodstream.
    • These antibodies belong to the IgGIgG class, which are small enough to readily cross the placenta.
    • Maternal IgGIgG anti-Rh antibodies pass into fetal circulation and destroy fetal Rh+Rh^+ RBCs, resulting in severe haemolysis.
  • Clinical Manifestations in the Fetus/Newborn:
    • Haemolytic anaemia.
    • Jaundice (hyperbilirubinemia resulting from excessive RBC breakdown).
    • Enlarged liver and spleen (hepatosplenomegaly).
    • Hydrops fetalis (generalized severe fetal oedema).
    • Heart failure (in severe presentations).
    • Stillbirth or early neonatal death if untreated.

Prophylactic Interventions and High-Yield Immunological Comparisons

  • Prevention of Erythroblastosis Foetalis:
    • Can be prevented by administering an Anti-D (Rh immunoglobulin / Anti-D Rh Ig) injection to the Rh−Rh^- mother.
    • Clinical Indications and Timing for Anti-D:
    • Within 72 hours72\,\text{hours} after the delivery of an Rh+Rh^+ baby.
    • Following a miscarriage or abortion.
    • Following an ectopic pregnancy.
    • Following invasive prenatal diagnostic procedures such as amniocentesis.
    • Mechanism of Action: Injected Anti-D immunoglobulin binds to and destroys fetal Rh+Rh^+ RBCs circulating in the mother's blood before her immune system can recognize the antigens and undergo primary sensitization.
  • High-Yield Immunological Distinctions:
    • Rh Antibodies (IgGIgG): Rh antibodies belong to the IgGIgG class, enabling them to cross the placenta and affect the fetus.
    • ABO Antibodies (IgMIgM): ABO antibodies belong primarily to the IgMIgM class, which are large pentameric structures that generally cannot cross the placental barrier.
    • Pregnancy Vulnerability: The initial Rh+Rh^+ pregnancy of an Rh−Rh^- mother is unaffected, whereas subsequent Rh+Rh^+ pregnancies carry a high risk of HDN if Anti-D prophylaxis is not administered.